Baird downgraded Instil Bio (TIL) to Neutral from Outperform with a price target of $7, down from $180, after the company discontinued clinical development of AXN-2510.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TIL: